<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-010867
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050408
<FILING-DATE>20050408
<DATE-OF-FILING-DATE-CHANGE>20050408
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05740344
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v016007_6k.htm
<TEXT>
<HTML><HEAD>
<TITLE>
</TITLE>
</HEAD><BODY id=38 bgColor=#ffffff>
<DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>SECURITIES
AND EXCHANGE COMMISSION</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Washington,
D.C. 20549</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><STRONG>FORM
6-K</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT OF
FOREIGN ISSUER</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule 13a-16 or 15d-16 of</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
Securities Exchange Act of 1934</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>For
the month of April 2005</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Commission
File Number 000-5112</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
Limited</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English) </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 12
BGC Centre</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28 The
Esplanade</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth WA
6000</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form&nbsp;20-F or Form&nbsp;40-F). </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 20-F
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If "Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule&nbsp;12g3-2(b): 82- ___. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>SIGNATURE
</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>
<TABLE cellSpacing=0 cellPadding=0 width="100%" align=center bgColor=#ffffff
border=0>
  <TR vAlign=top bgColor=#ffffff>
    <TD width="50%"><FONT face="Times New Roman" size=2>Date: April 8,
      2005</FONT></TD>
    <TD width="1%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD width="49%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD colSpan=2><FONT face="Times New Roman" size=2>pSivida
  Limited</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2></FONT></TD>
    <TD><FONT face="Times New Roman" size=2>By:&nbsp;&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>/s/&nbsp;Aaron Finlay</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD colSpan=2><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
    <TD align=left>
      <HR align=left width="80%" color=#000000 noShade SIZE=2>
      <FONT size=2>Aaron Finlay</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD colSpan=2><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2><EM>Chief Financial Officer and
      Company Secretary</EM></FONT></TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV><FONT size=2></FONT><BR>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV style="WIDTH: 100%" align=left>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV></DIV>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV><BR>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM><U>EXHIBIT
INDEX</U></EM></STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
  <TR>
    <TD vAlign=top align=left width="15%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>EXHIBIT
      99.1:</STRONG></FONT></DIV></TD>
    <TD vAlign=top align=left width="62%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Expands Market for Lead Cancer Product BrachySil</FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><SUP>TM</SUP></FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="15%">&nbsp;</TD>
    <TD vAlign=top align=left width="62%">&nbsp;</TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v016007_ex99-1.htm
<TEXT>
<HTML><HEAD>
<TITLE>
</TITLE>
</HEAD><BODY id=38 bgColor=#ffffff>
<DIV><BR>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=right><IMG src="logo.jpg"> </DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#ffffff>
  <TR bgColor=#ffffff>
    <TD width="50%"><STRONG><FONT size=2>ASX/MEDIA
      RELEASE</FONT></STRONG><FONT id=TAB2
      style="COLOR: black; LETTER-SPACING: 161.1pt">&nbsp;</FONT></TD>
    <TD width="50%">
      <DIV style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
      align=right><STRONG><FONT size=2>8<FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>th</SUP></FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      April 2005</FONT></FONT></STRONG></DIV></TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT id=TAB2
style="COLOR: black; LETTER-SPACING: 0.9pt">&nbsp;</FONT><FONT id=TAB2
style="COLOR: black; LETTER-SPACING: 27pt">&nbsp;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>&nbsp;</STRONG></FONT><FONT
id=TAB2 style="COLOR: black; LETTER-SPACING: 27pt">&nbsp;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>&nbsp;</STRONG></FONT><FONT
id=TAB2 style="COLOR: black; LETTER-SPACING: 27pt">&nbsp;</FONT><FONT id=TAB2
style="COLOR: black; LETTER-SPACING: 27pt">&nbsp;</FONT><FONT id=TAB2
style="COLOR: black; LETTER-SPACING: 27pt">&nbsp;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>
</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
Expands Market for Lead <BR>Cancer Product BrachySil</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><SUP><STRONG>TM</STRONG></SUP></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>Pancreatic
Cancer - Significant Unmet Clinical Need
<DIV>
<HR align=left width="100%" color=#000000 noShade SIZE=1>
</DIV></STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
nanotechnology company pSivida Limited </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>(ASX:PSD,
NASDAQ:PSDV, Xetra:PSI)</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> is
pleased to announce that it has initiated a full development programme of its
proprietary BrachySil</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> product
in a second key cancer indication. Development has commenced to evaluate the
efficacy and safety of this novel brachytherapy product in pancreatic cancer,
with the clinical programme scheduled to commence before the end of
2005.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Selection
of this second key indication has resulted from significant independent market
research and medical opinion leader feedback and therefore represents a
judicious, robust and viable development option.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pancreatic
cancer is one of the most prevalent cancers with over 232,000 new cases on a
global basis per annum (Globocan 2002 statistics) and approximately 60% of new
cases occurring in the developed world. With an average five year survival of
4%, pancreatic cancer represents a significant unmet clinical need.</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><EM>&nbsp;</EM></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> is a
micron-sized particle in which the isotope 32-phosphorus is immobilised. pSivida
believes that this product is unique in that it demonstrates a very high degree
of isotope retention, thus reducing the risk of radioactivity effecting healthy
hepatic tissue or entering the circulation and causing systemic toxicity.
</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
clinical programme currently being conducted in primary liver cancer has
provided significant data demonstrating the product&#8217;s safety, efficacy (up to
100% tumor regression in some cases for smaller tumors) and the ease of
administration via a fine gauge needle injection procedure. </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
ability of BrachySil&#8482; to remain at the injection site has been another
significant outcome of the trials. Multi-centre pivotal registration trials are
scheduled to commence during 2005 to provide data to support registration of
BrachySil&#8482; as an approved treatment for primary liver cancer.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
managing director Mr. Gavin Rezos said &#8220;This additional advanced development
programme for BrachySil</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> follows
the successful completion of the initial phase of clinical evaluation for the
product in primary liver cancer and is in line with our strategy to expand and
maximise the market potential of this unique approach to cancer therapy. This
second significant development programme will benefit enormously from the strong
foundation of pharmaceutical, manufacturing and clinical experience already
available for BrachySil</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">, and
therefore reduces risk in the pathway to regulatory approval and
commercialisation.&#8221;</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>-ENDS-</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR>
<DIV>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
  <TR>
    <TD vAlign=top width="31%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Released
      by:</STRONG></FONT></DIV></TD>
    <TD vAlign=top width="37%">&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="31%">&nbsp;</TD>
    <TD vAlign=top width="37%">&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="31%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>In
      Australia:</STRONG></FONT></DIV></TD>
    <TD vAlign=top width="37%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>In
      US:</STRONG></FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="31%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Josh
      Mann, CFA</FONT></DIV></TD>
    <TD vAlign=top align=left width="37%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
      Jedynak</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="31%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
      Relations</FONT></DIV></TD>
    <TD vAlign=top align=left width="37%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="31%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Limited</FONT></DIV></TD>
    <TD vAlign=top align=left width="37%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
      E. Janis &amp; Company, Inc.</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="31%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      + 61 8 9226 5099</FONT></DIV></TD>
    <TD vAlign=top align=left width="37%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      312-943-1100 ext. 12</FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top width="31%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: blue; FONT-FAMILY: Times New Roman"><U>joshuamann@psivida.com</U></FONT></DIV></TD>
    <TD vAlign=top width="37%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: blue; FONT-FAMILY: Times New Roman"><U>bjedynak@janispr.com</U></FONT></DIV></TD></TR></TABLE></DIV>
<DIV>&nbsp;</DIV></DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV><BR>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>NOTES
TO EDITORS:</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
Limited</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
is a global nanotechnology company committed to the biomedical sector and the
development of products in healthcare. The company&#8217;s focus is the development
and commercialisation of a modified form of silicon (porosified or
nano-structured silicon) known as BioSilicon&#8482;. As a new and exciting
biocompatible material, BioSilicon&#8482; offers multiple potential applications
across the high growth healthcare sector, including controlled release drug
delivery, targeted cancer therapies (including brachytherapy and localized
chemotherapy), tissue engineering and orthopedics. Potential diagnostics
applications are being developed through its subsidiary AION Diagnostics
Limited. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
owns the intellectual property rights to BioSilicon&#8482; for use in or on humans and
animals. The IP portfolio consists of 24 patent families, 26 granted patents and
over 80 patent applications. The core patent, which recognises BioSilicon&#8482; as a
biomaterial was granted in the UK in 2000 and in the US in 2001. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
is listed on NASDAQ (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSDV</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">), the
Australian Stock Exchange (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">) and in
Germany on the Frankfurt Stock Exchange on the XETRA system (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>German</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Symbol:
PSI. Securities Code (WKN) 358705</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
Market Service (IMS) under the ticker symbol </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
largest science and technology company in Europe. QinetiQ is the former UK
government Defence Evaluation Research Agency and was instrumental in
discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
having access to its cutting edge research and development facilities. For more
information on QinetiQ visit </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: blue; FONT-FAMILY: Times New Roman"><U>www.qinetiq.com</U>.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For more
information visit </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: blue; FONT-FAMILY: Times New Roman"><U>www.psivida.com</U></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif">This
document contains forward-looking statements that involve risks and
uncertainties. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no assurance
that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated in
these forward-looking statements due to many important factors including: our
failure to develop applications for BioSilicon</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: Arial, sans-serif"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"> due to
regulatory, scientific or other issues. Other reasons are contained in
cautionary statements in the Registration Statement on Form 20-F filed with the
U.S. Securities and Exchange Commission, including, without limitation, under
Item&nbsp;3.D, "Risk Factors" therein. We do not undertake to update any oral or
written forward-looking statements that may be made by or on behalf of
pSivida.</FONT></DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0VO17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-3HP-#HP
M,R`R,SHS-SHS.0```````Z`!``,````!``$``*`"``0````!````M*`#``0`
M```!````.0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```QY````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,P"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]5225;,MS*@'T-8]@'N:0XN)_-#/3#DS
M)D&.)F02!OPCB*@+;*2JTYCLC%-V/7-@.TU..V'`^]I="I.ZW<VTTG&'J!VS
M;O\`SIC]U09.?Y?'&$IS/#D`,)"$Y1E?C&/S?U%PB3]'1R\S%P<9^5F6LHQZ
MA+[;"&M`^)6,SJ/7>M:])K'3>GGZ/4,MA==8.S\/`=LV5_NW9G_L,B9'2\1V
M2>L]6:^^Z@C[-C6/%E-3AH'XU`977Z[W?X:WU;6?Z16?VAF5T/R;:01&VK&:
M'"YUI_FZ1Z@8SW?Z3^;9_.?S==BD^\8^..,69S'%P\)!C']Z?%\BPQD023PQ
M'X_5S\!W5,7ZSGIK\^WJ&,<,Y&1Z[:P:K#8*J/3?CUT[6WM;?^A=_HET2S>C
M=+LPJ[LC+<VWJ6<_ULVY@.W=&RJBG=[_`+-BU?H:-W_&_P`Y;8M)3(@"!JI)
M)5LSJ%&&!ZDN>[Z+&ZF/%,R988H&>20A".\I+@"=`V4E0Q>LXV18*R'5N=HW
M=$$_N[FH^=E'$H]4,]0R!MF.?DY1QYO!+%+-&8ECA\THZ\-?U?F3PFZIL)(6
M+<;\=EQ;L+Q.WP15+"0E$2CK&0$AY20I)9GUCZP_HO2K,^NC[2ZMS&^D"6SO
M<&?2:RSZ,_NJ?0>J/ZOTG'ZB^G[.Z\.)I))V[7.K^DYM?[F[Z"<MXQQ</Z5<
M7T=!)5\_,KP<'(S;6N=7C5OM>UL;B&`O<&S'N]JJ=`Z]B]>PG9F+7956RQU1
M;:`'2T-=/L<_V^])/$+$;U.M.FDDDDE__]#U5`S@#BOF(T)F".1^_P"U'6;U
M[K%/2L/<6.R,K)=Z.'B5F'W6N^A4QW^#;^?;=_@:_P!(F9(<<)P_>B8_XRK`
MU/1S3U*_IV-D?8\=V9EWW-IP\=GT38YKG;KGM]M.-6QF^VW]Q1?O_:/Z2#9Z
MK-^WC=+/4VS^9O\`H*^,7JE-HR:&,#WM'J5E[G:Q]&Q]I]_I_1]1CEFV.N.:
M7.:!?ZH)9VWR/;_G+G.=,L>#!@G"<98LTO7P^C)$RE*/MR_PF6(N1D#H1MV=
M?KA_04L[.M$CX`JQT]K/0W`-C<X@@-`\/\'[53.)U/*R&6Y(K8VOZ+9=[?Y3
M?2<';_\`KBU&,#&AK9@<223_`)SI<M;EH3R<UEYDPEC@0(0CD'!,\/Z7"ME0
MB!NR7'=1^N'6L;ZTW]$Q,2K+:&M;C5B6V.L=4R^;;G6>DRFO<]]OZ+^:78KS
M_P#_`#L_Z_\`<-:(Z^36SRD!#A-<4XQ/D6[T+ZV=</UC/0NO44UVV;MGH@C8
M\,^T,;N]2UMM5E/T'_36MU::^I,MM;OJ(:0.Q#3[V+F^J?\`Y4,/_K7_`)ZN
M7;Y%N!=9]BN+7O<?YLS(,;OI?F>U4_B.`9L(AQQQRXHRQ\?R2R#Y8'^\NY:<
MKF"3+AD8WUX6N[$P.I%M]3]NW1X9`=_)W_N[58ZCE68N-ZM8!=N`]TD:_P!4
MM63F8UG2\AEU#R6NG;/.GTJW_O-<K_67!_3@X<.<TCYJC'.8X><O&.7YO'$2
MRG'\L_3^KR0;%:QUN)V:'UAZWU/IWU=;U7#92^UKF>LVT.+`QY].6ACV.W>H
MZO\`/0,SZVW5?4VGKU3:_M=XK8VMP<:_5+_3O;M#VV;&[+MGZ1:-^!^T?JU;
M@P"[(QW,9/`>0?2=_9LVKRX9UN=]7L#H-1)O.:XM9X"T-KH_\'ON6MRQ,\&*
M4M9&$)2/G%I<QDECF:.DHD1']>^CWV1]9.KX_P!3*NNV5T#-MV.%9:_TMEEF
MROV^IZG\RYK_`.<5SIGUALM^J8Z]G,8'MJMMLKJEK3Z;K&L8SU#8[W[&JG]>
MJ*\;ZGOQZA%5)HK8/!K7UL;_`-$+/I__`"5N_P")?_Y_<I:%?51G..0QN^'%
MQ?X8ZM)OUG^M?5>B=3R;L&J_I;ZK:+'TG8^DED&QHL>]V331O_3^Q:?^+K(I
MQ?JMEY-[ME-&1=98[P:RNI[W?YK4#ZN__DXZC_Q>9_U+D;_%YD8^+]5<O)RG
M!F/3D7/M<1(#6LJ<_P!OYR1V*S&3QXY2E9,)'5H-^NWUNZE5D]1Z3A4CIN(2
M;"X;W!H&_P#2.]:KU+&U^^UF.S]$NI^JGUA_;_3/M3ZQ3D5/-5[&F6[@`[?7
M/N]-['?G+F;.N?63ZQXF;9TFJOIG1:&6>K:]H=;8`PE]7YS&V/9]/TF_H?\`
MN0K?^*W_`)*S(X^T#_SW6D1HG'.7NQ'$91D";D*CI^X__]'U*VVNFM]MK@RN
MMI<][C`#6C<YSC_)7/\`U>ILZOEN^M&:T@6@U](H>(-.*3_/[?S<G/\`YRQ_
M^@].KU/35GZT9&!]A_9>=D?8J^JMLQF91@-8\MW-:\NVM_2-W?G>]-E?6KZM
M],KKQV95=M@:&48F)^GL(`VLKKIQ]_\`TD6,D<6I`$?^D[:Y3)R-W5[J<5HO
MOKN!L$Q75)&S[5?[O3<__!X[-^3;_HU89_SDZZ9M#^@]+/YC2#G6C^4]NZOI
M['?\'ZF5_P`)6K=7U>91773C6MHII,U55LT!_P!(=SW.LN=]*R^W?;8J'Q'E
MSECCK'+*<<N,0C*..-_ZR4Y0]/\`<_\`&V2$B;KT@_I'?_!#JU-L:R+'[W\N
M<!M']EONVM_M*:%0RYC-MUOK/GZ>T-T\-K4578DD`F)B3^C*KC_B<45*7FW4
MZ<V__&5;5@7C%S"&FFXM#VAS<4/V6,/^#M:/2>O25S__`#3_`.RW_G)]K_\`
M07T_^!^R?SV__KG\VG`U?DPYX&8@!TG&1UKTN3T+ZL?6"SZSGKW7G5!]4E@K
M(.]VS[/7L8T?HJ:JB[Z7Z3>NDZETQ]]C<C'<&W")!,3'T7-</HO:M))0\S@Q
M\QC./(+CH17IE&4=I19,41C^6]39O6[<8=,ZAE6M=G/&QNAU!,>#0T!ON_>5
M[J6-9DXOI4QNW`P=!`5M)00^'X88\N.YR]\5ER3EQ99_X3(9FP>R#"J?3BU5
M/C<QL&-0N,P/J/GX_P!;OVB\5?LRO(MR*@''?[@Y]#/3V_X.ZS][_!+NDE;Q
MQ&.$81VB!$>46+)CC,@R_1/$'&^MW2LSJW0[<'#V&][ZW#>=K8:]KW>Z'>"#
MTKZOW-^J#>A9Y:RU]-M3W,]X:7NL<Q[?H;MF]CUOI)UJ..)D9'<QX/\`!?/>
MF_57ZZ8^#E]'-]./T^T6.>6$/=8XM+/2I<6[Z:<AVSUO4_,_FUJ]$^JF?3]4
M\[HN<YE5^6^QS'5N+VC<VOTR[VM_PE?O76I)65D>7A'N:!CJ?T9/GW3/JS]>
M*L"[HYR*</I[]Y<YI%CW;@9JI<`',JO?_.;_`*'_`(&MSZC=!ZCT3!R:,\5A
M]MPL9Z;MPC8UG[K?W5TJ21*88(Q(())B*%GH_P#_TNZ^M^W]BOW?L_;O;/[5
MG[/_`.!^_P!;_1[50^I.W;;M_8L1I^R-V[_K_J>]?/Z22P_-^C_W3]5)+Y52
M27OU4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U
M4DOE5))3]5)+Y5224__9_^T2:E!H;W1O<VAO<"`S+C``.$))300E```````0
M`````````````````````#A"24T#[0``````$`!(`````0`!`$@````!``$X
M0DE-!"8```````X`````````````/X```#A"24T$#0``````!````'@X0DE-
M!!D```````0````>.$))30/S```````)```````````!`#A"24T$"@``````
M`0``.$))32<0```````*``$``````````CA"24T#]0``````2``O9F8``0!L
M9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:````!@``````
M`0`U`````0`M````!@```````3A"24T#^```````<```________________
M_____________P/H`````/____________________________\#Z`````#_
M____________________________`^@`````________________________
M_____P/H```X0DE-!`````````(``3A"24T$`@``````!``````X0DE-!`@`
M`````!`````!```"0````D``````.$))300>```````$`````#A"24T$&@``
M```#20````8``````````````#D```"T````"@!5`&X`=`!I`'0`;`!E`&0`
M+0`Q`````0`````````````````````````!``````````````"T````.0``
M```````````````````!`````````````````````````!`````!````````
M;G5L;`````(````&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4
M;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG````.0``
M``!29VAT;&]N9P```+0````&<VQI8V5S5FQ,<P````%/8FIC`````0``````
M!7-L:6-E````$@````=S;&EC94E$;&]N9P`````````'9W)O=7!)1&QO;F<`
M````````!F]R:6=I;F5N=6T````,15-L:6-E3W)I9VEN````#6%U=&]'96YE
M<F%T960`````5'EP965N=6T````*15-L:6-E5'EP90````!);6<@````!F)O
M=6YD<T]B:F,````!````````4F-T,0````0`````5&]P(&QO;F<`````````
M`$QE9G1L;VYG``````````!"=&]M;&]N9P```#D`````4F=H=&QO;F<```"T
M`````W5R;%1%6%0````!````````;G5L;%1%6%0````!````````37-G951%
M6%0````!```````&86QT5&%G5$585`````$```````YC96QL5&5X=$ES2%1-
M3&)O;VP!````"&-E;&Q497AT5$585`````$```````EH;W)Z06QI9VYE;G5M
M````#T53;&EC94AO<GI!;&EG;@````=D969A=6QT````"79E<G1!;&EG;F5N
M=6T````/15-L:6-E5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y
M<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T
M<V5T;&]N9P`````````*;&5F=$]U='-E=&QO;F<`````````#&)O='1O;4]U
M='-E=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N9P``````.$))300H````
M```,`````3_P````````.$))3004```````$`````CA"24T$#``````,E0``
M``$```"@````,P```>```%^@```,>0`8``'_V/_@`!!*1DE&``$"`0!(`$@`
M`/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,P"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]5225;,MS*@'T-8]@'N:
M0XN)_-#/3#DS)D&.)F02!OPCB*@+;*2JTYCLC%-V/7-@.TU..V'`^]I="I.Z
MW<VTTG&'J!VS;O\`SIC]U09.?Y?'&$IS/#D`,)"$Y1E?C&/S?U%PB3]'1R\S
M%P<9^5F6LHQZA+[;"&M`^)6,SJ/7>M:])K'3>GGZ/4,MA==8.S\/`=LV5_NW
M9G_L,B9'2\1V2>L]6:^^Z@C[-C6/%E-3AH'XU`977Z[W?X:WU;6?Z16?VAF5
MT/R;:01&VK&:'"YUI_FZ1Z@8SW?Z3^;9_.?S==BD^\8^..,69S'%P\)!C']Z
M?%\BPQD023PQ'X_5S\!W5,7ZSGIK\^WJ&,<,Y&1Z[:P:K#8*J/3?CUT[6WM;
M?^A=_HET2S>C=+LPJ[LC+<VWJ6<_ULVY@.W=&RJBG=[_`+-BU?H:-W_&_P`Y
M;8M)3(@"!JI))5LSJ%&&!ZDN>[Z+&ZF/%,R988H&>20A".\I+@"=`V4E0Q>L
MXV18*R'5N=HW=$$_N[FH^=E'$H]4,]0R!MF.?DY1QYO!+%+-&8ECA\THZ\-?
MU?F3PFZIL)(6+<;\=EQ;L+Q.WP15+"0E$2CK&0$AY20I)9GUCZP_HO2K,^NC
M[2ZMS&^D"6SO<&?2:RSZ,_NJ?0>J/ZOTG'ZB^G[.Z\.)I))V[7.K^DYM?[F[
MZ"<MXQQ</Z5<7T=!)5\_,KP<'(S;6N=7C5OM>UL;B&`O<&S'N]JJ=`Z]B]>P
MG9F+7956RQU1;:`'2T-=/L<_V^])/$+$;U.M.FDDDDE__]#U5`S@#BOF(T)F
M".1^_P"U'6;U[K%/2L/<6.R,K)=Z.'B5F'W6N^A4QW^#;^?;=_@:_P!(F9(<
M<)P_>B8_XRK`U/1S3U*_IV-D?8\=V9EWW-IP\=GT38YKG;KGM]M.-6QF^VW]
MQ1?O_:/Z2#9ZK-^WC=+/4VS^9O\`H*^,7JE-HR:&,#WM'J5E[G:Q]&Q]I]_I
M_1]1CEFV.N.:7.:!?ZH)9VWR/;_G+G.=,L>#!@G"<98LTO7P^C)$RE*/MR_P
MF6(N1D#H1MV=?KA_04L[.M$CX`JQT]K/0W`-C<X@@-`\/\'[53.)U/*R&6Y(
MK8VOZ+9=[?Y3?2<';_\`KBU&,#&AK9@<223_`)SI<M;EH3R<UEYDPEC@0(0C
MD'!,\/Z7"ME0B!NR7'=1^N'6L;ZTW]$Q,2K+:&M;C5B6V.L=4R^;;G6>DRFO
M<]]OZ+^:78KS_P#_`#L_Z_\`<-:(Z^36SRD!#A-<4XQ/D6[T+ZV=</UC/0NO
M44UVV;MGH@C8\,^T,;N]2UMM5E/T'_36MU::^I,MM;OJ(:0.Q#3[V+F^J?\`
MY4,/_K7_`)ZN7;Y%N!=9]BN+7O<?YLS(,;OI?F>U4_B.`9L(AQQQRXHRQ\?R
M2R#Y8'^\NY:<KF"3+AD8WUX6N[$P.I%M]3]NW1X9`=_)W_N[58ZCE68N-ZM8
M!=N`]TD:_P!4M63F8UG2\AEU#R6NG;/.GTJW_O-<K_67!_3@X<.<TCYJC'.8
MX><O&.7YO'$2RG'\L_3^KR0;%:QUN)V:'UAZWU/IWU=;U7#92^UKF>LVT.+`
MQY].6ACV.W>HZO\`/0,SZVW5?4VGKU3:_M=XK8VMP<:_5+_3O;M#VV;&[+MG
MZ1:-^!^T?JU;@P"[(QW,9/`>0?2=_9LVKRX9UN=]7L#H-1)O.:XM9X"T-KH_
M\'ON6MRQ,\&*4M9&$)2/G%I<QDECF:.DHD1']>^CWV1]9.KX_P!3*NNV5T#-
MMV.%9:_TMEEFROV^IZG\RYK_`.<5SIGUALM^J8Z]G,8'MJMMLKJEK3Z;K&L8
MSU#8[W[&JG]>J*\;ZGOQZA%5)HK8/!K7UL;_`-$+/I__`"5N_P")?_Y_<I:%
M?51G..0QN^'%Q?X8ZM)OUG^M?5>B=3R;L&J_I;ZK:+'TG8^DED&QHL>]V331
MO_3^Q:?^+K(IQ?JMEY-[ME-&1=98[P:RNI[W?YK4#ZN__DXZC_Q>9_U+D;_%
MYD8^+]5<O)RG!F/3D7/M<1(#6LJ<_P!OYR1V*S&3QXY2E9,)'5H-^NWUNZE5
MD]1Z3A4CIN(2;"X;W!H&_P#2.]:KU+&U^^UF.S]$NI^JGUA_;_3/M3ZQ3D5/
M-5[&F6[@`[?7/N]-['?G+F;.N?63ZQXF;9TFJOIG1:&6>K:]H=;8`PE]7YS&
MV/9]/TF_H?\`N0K?^*W_`)*S(X^T#_SW6D1HG'.7NQ'$91D";D*CI^X__]'U
M*VVNFM]MK@RNMI<][C`#6C<YSC_)7/\`U>ILZOEN^M&:T@6@U](H>(-.*3_/
M[?S<G/\`YRQ_^@].KU/35GZT9&!]A_9>=D?8J^JMLQF91@-8\MW-:\NVM_2-
MW?G>]-E?6KZM],KKQV95=M@:&48F)^GL(`VLKKIQ]_\`TD6,D<6I`$?^D[:Y
M3)R-W5[J<5HOOKN!L$Q75)&S[5?[O3<__!X[-^3;_HU89_SDZZ9M#^@]+/YC
M2#G6C^4]NZOI['?\'ZF5_P`)6K=7U>91773C6MHII,U55LT!_P!(=SW.LN=]
M*R^W?;8J'Q'ESECCK'+*<<N,0C*..-_ZR4Y0]/\`<_\`&V2$B;KT@_I'?_!#
MJU-L:R+'[W\N<!M']EONVM_M*:%0RYC-MUOK/GZ>T-T\-K4578DD`F)B3^C*
MKC_B<45*7FW4Z<V__&5;5@7C%S"&FFXM#VAS<4/V6,/^#M:/2>O25S__`#3_
M`.RW_G)]K_\`07T_^!^R?SV__KG\VG`U?DPYX&8@!TG&1UKTN3T+ZL?6"SZS
MGKW7G5!]4E@K(.]VS[/7L8T?HJ:JB[Z7Z3>NDZETQ]]C<C'<&W")!,3'T7-<
M/HO:M))0\S@Q\QC./(+CH17IE&4=I19,41C^6]39O6[<8=,ZAE6M=G/&QNAU
M!,>#0T!ON_>5[J6-9DXOI4QNW`P=!`5M)00^'X88\N.YR]\5ER3EQ99_X3(9
MFP>R#"J?3BU5/C<QL&-0N,P/J/GX_P!;OVB\5?LRO(MR*@''?[@Y]#/3V_X.
MZS][_!+NDE;QQ&.$81VB!$>46+)CC,@R_1/$'&^MW2LSJW0[<'#V&][ZW#>=
MK8:]KW>Z'>"#TKZOW-^J#>A9Y:RU]-M3W,]X:7NL<Q[?H;MF]CUOI)UJ..)D
M9'<QX/\`!?/>F_57ZZ8^#E]'-]./T^T6.>6$/=8XM+/2I<6[Z:<AVSUO4_,_
MFUJ]$^JF?3]4\[HN<YE5^6^QS'5N+VC<VOTR[VM_PE?O76I)65D>7A'N:!CJ
M?T9/GW3/JS]>*L"[HYR*</I[]Y<YI%CW;@9JI<`',JO?_.;_`*'_`(&MSZC=
M!ZCT3!R:,\5A]MPL9Z;MPC8UG[K?W5TJ21*88(Q(())B*%GH_P#_TNZ^M^W]
MBOW?L_;O;/[5G[/_`.!^_P!;_1[50^I.W;;M_8L1I^R-V[_K_J>]?/Z22P_-
M^C_W3]5)+Y5227OU4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+Y522
M4_522^54DE/U4DOE5))3]5)+Y5224__9`#A"24T$(0``````4P````$!````
M#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!(`00!D`&\`8@!E
M`"``4`!H`&\`=`!O`',`:`!O`'``(`!#`%,````!`#A"24T$!@``````!P`$
M`````0$`_^$7^6AT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C
M:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G
M/SX*/'@Z>&UP;65T82!X;6QN<SIX/2=A9&]B93IN<SIM971A+R<@>#IX;7!T
M:STG6$U0('1O;VQK:70@,RXP+3(X+"!F<F%M97=O<FL@,2XV)SX*/')D9CI2
M1$8@>&UL;G,Z<F1F/2=H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D
M9BUS>6YT87@M;G,C)R!X;6QN<SII6#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]I
M6"\Q+C`O)SX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IC
M-61E935A,BUA-&)A+3$Q9#DM.#8P-BTX-S,R8F,T,C$Y-V,G"B`@>&UL;G,Z
M97AI9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\G/@H@(#QE>&EF
M.D-O;&]R4W!A8V4^,3PO97AI9CI#;VQO<E-P86-E/@H@(#QE>&EF.E!I>&5L
M6$1I;65N<VEO;CXQ.#`\+V5X:68Z4&EX96Q81&EM96YS:6]N/@H@(#QE>&EF
M.E!I>&5L641I;65N<VEO;CXU-SPO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B`\
M+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TG=75I9#IC-61E935A,BUA-&)A+3$Q9#DM.#8P-BTX-S,R8F,T,C$Y-V,G
M"B`@>&UL;G,Z<&1F/2=H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O)SX*
M(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2=U=6ED.F,U9&5E-6$R+6$T8F$M,3%D.2TX-C`V+3@W,S)B8S0R,3DW
M8R<*("!X;6QN<SIP:&]T;W-H;W`])VAT='`Z+R]N<RYA9&]B92YC;VTO<&AO
M=&]S:&]P+S$N,"\G/@H@(#QP:&]T;W-H;W`Z2&ES=&]R>3X\+W!H;W1O<VAO
M<#I(:7-T;W)Y/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70])W5U:60Z8S5D964U83(M831B82TQ,60Y+3@V,#8M
M.#<S,F)C-#(Q.3=C)PH@('AM;&YS.G1I9F8])VAT='`Z+R]N<RYA9&]B92YC
M;VTO=&EF9B\Q+C`O)SX*("`\=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R
M:65N=&%T:6]N/@H@(#QT:69F.EA297-O;'5T:6]N/C<R+S$\+W1I9F8Z6%)E
M<V]L=71I;VX^"B`@/'1I9F8Z65)E<V]L=71I;VX^-S(O,3PO=&EF9CI94F5S
M;VQU=&EO;CX*("`\=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L
M=71I;VY5;FET/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70])W5U:60Z8S5D964U83(M831B82TQ,60Y+3@V,#8M
M.#<S,F)C-#(Q.3=C)PH@('AM;&YS.GAA<#TG:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+R<^"B`@/'AA<#I#<F5A=&5$871E/C(P,#4M,#0M,#-4,C,Z
M,S<Z,SDM,#4Z,#`\+WAA<#I#<F5A=&5$871E/@H@(#QX87`Z36]D:69Y1&%T
M93XR,#`U+3`T+3`S5#(S.C,W.C,Y+3`U.C`P/"]X87`Z36]D:69Y1&%T93X*
M("`\>&%P.DUE=&%D871A1&%T93XR,#`U+3`T+3`S5#(S.C,W.C,Y+3`U.C`P
M/"]X87`Z365T861A=&%$871E/@H@(#QX87`Z0W)E871O<E1O;VP^061O8F4@
M4&AO=&]S:&]P($-3(%=I;F1O=W,\+WAA<#I#<F5A=&]R5&]O;#X*(#PO<F1F
M.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U
M=6ED.F,U9&5E-6$R+6$T8F$M,3%D.2TX-C`V+3@W,S)B8S0R,3DW8R<*("!X
M;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R<^
M"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.F,U
M9&5E-6$Q+6$T8F$M,3%D.2TX-C`V+3@W,S)B8S0R,3DW8SPO>&%P34TZ1&]C
M=6UE;G1)1#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2=U=6ED.F,U9&5E-6$R+6$T8F$M,3%D.2TX-C`V+3@W
M,S)B8S0R,3DW8R<*("!X;6QN<SID8STG:'1T<#HO+W!U<FPN;W)G+V1C+V5L
M96UE;G1S+S$N,2\G/@H@(#QD8SIF;W)M870^:6UA9V4O:G!E9SPO9&,Z9F]R
M;6%T/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX;7!M
M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*/#]X<&%C:V5T(&5N9#TG=R<_/O_B#%A)0T-?4%)/1DE,10`!`0``
M#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94````
M`$E%0R!S4D="``````````````````#VU@`!`````-,M2%`@(```````````
M````````````````````````````````````````````````````$6-P<G0`
M``%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````%')8
M65H```(8````%&=865H```(L````%&)865H```)`````%&1M;F0```)4````
M<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU;6D```/X
M````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=44D,`
M``0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX
M($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%
M0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````````
M``````````````````````````````````````````````````````````!8
M65H@````````\U$``0````$6S%A96B``````````````````````6%E:(```
M`````&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B`````````D
MH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H````
M```````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````````
M`````````````````````````````````````````&1E<V,`````````+DE%
M0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``
M````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P
M86-E("T@<U)'0@````````````````````````````!D97-C`````````"Q2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````
M```````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q
M.38V+3(N,0``````````````````````````````````=FEE=P``````$Z3^
M`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M
M96%S``````````$````````````````````````"CP````)S:6<@`````$-2
M5"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`
M2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W
M`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!
M.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9
M`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("
MK`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B
M`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$
MTP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G
M!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'
MOP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY
M"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+
M@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI
M#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0
M)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#
M$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5
MO17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W&!L80!AE&(H8KQC5
M&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;8QN*&[(;VAP"'"H<
M4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I'Q,?/A]I'Y0?OQ_J
M(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\BW2,*(S@C9B.4(\(C
M\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H)Q@G22=Z)ZLGW"@-
M*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K:2N=*]$L!2PY+&XL
MHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^,#4P;#"D,-LQ$C%*
M,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U$S5--8<UPC7]-C<V
M<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ
M.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!
M:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U
M1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-
MDTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V
M5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:
M]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U
M8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-I
MFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z
M<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IY
MB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-
M@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*
MRHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.V
ME""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=
M9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]
MIVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ
M8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNG
MO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&
MP\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^
MTC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=
MEMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&
MZ=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#U
MWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N``Y!9&]B
M90!D``````'_VP"$``8$!`0%!`8%!08)!@4&"0L(!@8("PP*"@L*"@P0#`P,
M#`P,$`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!!P<'#0P-&!`0&!0.
M#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#/_``!$(`#D`M`,!$0`"$0$#$0'_W0`$`!?_Q`&B````!P$!`0$!
M```````````$!0,"!@$`!P@)"@L!``("`P$!`0$!``````````$``@,$!08'
M"`D*"Q```@$#`P($`@8'`P0"!@)S`0(#$00`!2$2,4%1!A-A(G&!%#*1H0<5
ML4(CP5+1X3,68O`D<H+Q)4,T4Y*BLF-SPC5$)Y.CLS875&1TP]+B"":#"0H8
M&82414:DM%;352@:\N/SQ-3D]&5UA96EM<75Y?5F=H:6IK;&UN;V-T=79W>'
MEZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*
MVNKZ$0`"`@$"`P4%!`4&!`@#`VT!``(1`P0A$C%!!5$382(&<8&1,J&Q\!3!
MT>$C0A528G+Q,R0T0X(6DE,EHF.RP@=STC7B1(,75),("0H8&28V11HG9'15
M-_*CL\,H*=/C\X24I+3$U.3T976%E:6UQ=7E]4969G:&EJ:VQM;F]D=79W>'
MEZ>WQ]?G]SA(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:
MZOK_V@`,`P$``A$#$0`_`/5.*NQ5V*NQ5V*I-YF\WZ#Y;M5GU2XX22GC:VD8
M,EQ._9(HE^-VP@6U9<\<8]3'XG_,SS&/61HO*&F-O$CQK>:BZ^+JQ]""O\M)
M77#L/-Q_WV3_`&J/^FR-?ESJOF276/,VBZM??I:WT6YA@M-3:-(G=I(_4DC<
M1@(3%5<9`+I9S,I1D>(0/U,ZR+FNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*O_T/5.*H;4+N:U@$D5L]R>5"B$`@4)Y;YAZW4SPPXHPEFW^F'^Z91%J.EZ
MS::B)%C#1SPFDL+TY+]U01E'9W:N+56(W&</KQS^J*9P,4)=^:]/M)6CGAN$
M()4$QT#<32JDG<9@ZGVDP8)&,XY8[_S/JX?YOJ9#"3R0MSYCDU*U>VT5Y+:]
ME(2.\EMO7CB+;<F0.G3W;):3VCP9YB,(996>'Z/3'B_G^KTL<N"?#L1$I9IO
MEO0?*UXNH7LDVN>:KP4DU*YXM.P_EC!/"WA[*D?_``V9O:7;&/3$1-SR3^C%
M#ZG'T^B`/$?5+^?)-=:\R7]MHX-I9-^F[US;:78R$'E*17U'*]((E_>2M_(O
M\S+F1H<\LT.*4)8?Z,DZB?`*CZI2^G\?T41Y0\LP>7-$CT])3<W+N]Q?WC_;
MGN9CREE;_6;I_*O%<RR;8X,(QQKK_%_2DG6!N=BJR::*&-I97$<:BK.QH!])
MRO+ECCB92(C&/\4D@6EZ>9M">01K=IR)H"0P'_!$4S50]H-%*7",D;_SHQ_T
MU<+/PI=R9@@@$&H/0YN`;:TMM_,%A/J;Z<@?ZPA922HXU3KO7-3@[;P9-0=/
M'B\2)D.7I_=_%L.,@6F6;=K=BK&?//YA:#Y+MK6XUA9VCO':.+ZN@D/)%Y&M
M67)1C;CZC51P@&75.](U.VU72K/4[4,+:]ACN(0XHW"10R\A4T-#@(;<<Q*(
MD.4D3)(D<;2.>*("S,>P`J3@9DI-Y=\Z^5O,CSIH>HQ7S6P5IQ'R^$/7C7D!
MUXG"00TXL\,GTFT[P-SL5=BK_]'U3BJV50T3J14%2"#3P]]LAD%Q(\DAA6DR
MK#YFM3&R\9D:-PAB(Z'_`'S11T&>>=FY1#M&'"162)A+A.'N/_*-Z/X8N5,7
M`J'F3S+I&M>M!ILWUC]%W)MKJ516/U2G(HC='*?MT^RV;+VU%8L?]:7W!HT>
M:,Y2`_A3CR'_`,<^Y_XS?\:C)^QG]Q/_`(9_O8MFHYA++Z59O,EZTI6D=(D#
MF$"@H.DU5/T9J-9D&3M#*9$>G]W'B.'_`+&?3_I6R(J`9FEG;K<?6>`,_`1*
MYZJG7BO\H)W;^;_8KGH\10IPJ%VK84L!N?SN\CV>N:EH][)<6L^E>J+F:6-1
M$6A(4K&0Q=V8GX%X?%D^`N">T,8D8G;A4O)WYY>3_-&MKH]M'<VEU-R^J-<J
M@28J">(*,_%Z"O%L3`A&#M''DEPBP4U\_7$H%I`"1$W)V'8L*`?=7.!]M,TA
MX</X#Q2_SMG<Z<<RM/E&RN-%CGL7,EVR*X8L.+D_:7P7`?9C#ET<9X3Q9C$2
M^KT3_G0_H_CB7QB)4>2>^7;+4++3EM[UE9D)]/B2:(?V2?8YTG8>DSZ?3C'F
M()B?1P^KAA_-:<L@380MG=Z`VO20P6S+J(:0/,1L2*\M^7?Y9A:74Z&6ME"$
M"-1Q3XI_TO\`*?Q?[UE(2X=SLE<OYJ>6X?.Z^39HKJ+5FD6)':-?0)>/U%(?
MGRHR]/@^UG3\)JW7'6P&3P]^)?YZ_-#RWY+FLX=66XDEO5=XDMD60A8R`2W)
MDI4M\.,8DIU.LAA($KW2S\U=;_+^RTO2[CSEI<M_;SNQLXE0,T;E`6Y#U$I\
M.W5L,0>C7K,F*,0<@ME6BZCHD?E2RU&T'U/1$LHYX%D''TK81!EY"K4X1^^1
M/-R<<X^&"-H</^Q>?Q?\Y">0M2N+G32;BSCECDCM[ZX15A=BI`KQ9G3EVYK_
M`*W')^&7!':F*1,=Q_28I_SBU_O=YA_XQ6O_`!*7)97$[&YR^#TCSQ^<GE#R
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M&`2S#B!MVP^SG:VGTFGGXDO5Q\48?Q2](9YL9D=F_+\4U_J$]VK@&>3U)E1V
M4HO(FA^`JWRYY+L7'/4YYY0?[R?'/AG.'AQXO^%RA/\`Y6+D/"*9IGH3B.Q5
M\V>6]/L;_P#YR-U""]@CN8!>WT@BE4.O-$9E;B=OA.XR\GTO/8H"6K((OU2_
M2U^9EI;:3^>VD2Z?$MOZLVG3LL8"KS,W!C04'Q*OQ8QWBC61$=5&MOI?0FM:
M-;ZI:^E(>$B'E%*-RI_B#FD[6[*QZW'P2],H_1/^;_QUZ7',Q+#V37_+<]0?
MW#'J/BA?YC]D_P##9P,HZ[LF=_Y,G^M@R?\`$R_TLG*].0,ST?58=3LEN8QQ
M:O&2/KQ8=1GH/97:4-9A&2.Q^F<?YDW%G#A-,7TG_E-KC_C)/_'.-[,_XV)_
MU\O^^<B?]V'F/Y^6\F@_F%Y=\UP`J']-G8=Y+*4,?OC=1GI./<4\MVF.#+&?
MX]"GY^X^;?SYT?1T/JV=I]51P-P8U!NY?O1N.,=HHU/[W51CT%?\6G/_`#E'
M_P`<70O^8F;_`)-C!B;NV?IC[T[\R320_P#..RO&:,=&LT)'\L@B1O\`A6P#
MZF[*:TG^9']"1?D5Y=T.]_+'6)[RRAN9+FXN(Y6E17)2.%."@D5'$EF%/VL.
M0[M'9N*)PR)%_P!B6?\`.+7^]WF'_C#:_P#$I<.5K[&YR^#)/,'E#\K?*/FB
M?S=YGU.2ZO;N26XCTVY$<P9Y#U2%4YL(_LIR^!<B)$B@Y.7!@Q3\29LG^&3S
M+2]9T35/SPTK4_+]HVG:;<W]N8K<HL1W4)(W!"542'DU!_-EA'IW=;#)&6I!
M@.&/$'U9F.]._P#_T_5.*L'_`#`\S:H;NU\G>6G`\R:NI9[GJ+&S&TER_P#E
M?LQ?Y?\`L<E$=2X>IRRL8X?7+_81_G)_Y;\I:+Y?T*#1;.`-;1?%(T@#-+*W
MVY9"?M.YZG*LV..05,"8[I>IR,&(8XU%)?.FFV%I#;/;0)"SNP<H*5`&<%[6
M:#!AA`XX1QF4I7PN?@D3=K?*-MI,L#_6XHY;AI>,*,.3%0H)HO\`*.[9/V3[
M/P9L,Y9(1R2C/^+^J&.HR&)`MF<4442!(D6-!T50`/N&=UCQ1@*B!&/]'TN.
M3:[)H=BKYBTWS#I7E_\`YR!U/4]5F^KV*7U[')-0L%,JLBEN-3QY'?+R+B\W
M#+&&K)ERXI+O.&L:?YN_/'2'T247=LL]C`DZ`\6]&3U9&6H'PH"V_P#DXQ%1
M7/D&74QX=_I>[><+W6+,0RVDQCM7'&3B!4/U%217XAG$^U&KU>GX98I<.*7I
MEP@?7_6_I?[UZS!&)Y\T+JGFO3KW1)("C&ZE4*8RNRM_-RZ;=LP^T/:33ZC1
MF%'Q9Q^BOIE_.XO]RRAA(EY(KR+;RQZ=-,X(2:2L=>X44)^_,SV.P2CIY2/+
M)+T_YO\`%^/YK'4'=+])_P"4VN/^,D_\<U?9G_&Q/^OE_P!\SG_=A(O^<B]#
M^O\`D`WR+672KF.<GOZ<G[E_^)JW^QST?&=W0]JX^+%?\TL$_P"<<M/N-5\Y
M:GK]XQE>QM5B$K?[\FHB_=%$RY/+L*<'LF)ED,S_``A/_P#G*/\`XXNA?\Q,
MW_)L9'$Y';/TQ]Z?Z[9S7G_./2PPJ6D&BVLO$=:0I'*W_"H<`^IOR1O2?YD6
M$_DW^8OE30OR^U73-5O!;WJSS200<69YA-$JJ(PH/)N:E:9*<22X?9^JA#$8
MR.Z__G%L$7_F$$4(BM01_LI<<J]C<Y?!C7E#5_+.J_FCJ>J_F%.O!&F>!+H$
MP^M')Q2)UH?@BCY<(S\/PY(@@;./@R0EG,LJM-Y@TC7_`,_-+U+1ZG3FO;.*
MW8IZ8(A18R57LE5^'_)QJHI.6,]4#'Z;B^H<QWI7_]3U%?7<5E8W%Y+7TK:)
MYI*=>,:EC3Z!BQE*@3W,)_*72KB;3;CSCJ@Y:UYG;ZTY._I6G_'M`A[(L=&_
MZYR<CT<310)!R2^K)_N?X6=RRQ0QM+*ZQQ("SNY"JH'4DG89!S":>;^9?-4/
MF8I;^7&62RM)&%WKTRDV:M2A2W&S7DW^3'^Z7]N7.?\`:'28)PA+43\/'C)E
MPQ_O,O\`0@UX=3*9(Q#B_P!L_P`G'_BTY\@KI%G!/&L@^MRR`-<7#*;B?84+
M'8=?LQ1CTX_V<QNP.U<$XRA$0T\1/APXK]?#_.E_JF2<G(E@,=]YR_BFS'.I
M8.Q5V*OF[RS9VE[_`,Y%:M:7<*7%M-<:BDT$BAD93&]0RG8Y>?I>>PQ!U9!Y
M7+]+VKR[^6?D?R[J+ZEI&EQV]ZP*B8M)(45NHC]1F"5_R<J,B7<8M)CQFXC=
MDLT,4T;12H)(W%&1A4$?+*<N*.2)C(<49?PR<H&DL7RKH*R<Q:@GK0LQ7[B:
M9J(^SFA$N+P_MEP_Z7B;/&EWIHJ*BA4`55%%4"@`]LW,8B(H"@&I"Q:1IT5X
MUY'`%N6+%I*FI+=>],PL?9FGAE.:,:RF_7O_`!_4R,R12[4],L-4T^?3]0A6
MXLKI#'/"U:,IZC:AS/:YP$A1Y(#RWY0\M^6H9H=#L4L8[A@\ZH6;DRB@)+EC
ML,))+#%@AC%1%.\R>3_+?F6&"'7+%+Z.V8O"KLZ\684)^!E[8@D+EP0R?4+3
M"ST^RL]/AT^VB6.RMXE@B@ZJ(U7B%^*M1QVWP6SC``4.3&M,_*C\O=+U8:K9
M:-#'>JW.-B7=(V_FCC=FC0^'%?A_9R1F7'AHL49<0CNF/ESR1Y5\MRW$NB:>
MEE)=A1<,C.W/B25KS9NG)L!D2V8M/#'](JTLU7\I/R\U759-5OM'CDO)FYS,
M'D19'/5G1&5&)_:^'XOVL(F6J>AQ2EQ&.Z+/Y<>1_P!+VVKKI$*:C:>E]6FC
MYIP]$`1\41@GP@?RX\19_E,?$)5N&29%R'__U?0GG_4]?TK1H=1T;3VU5K:Y
M1K[3TW>6U9'20(`&)92R/]EOLY*(<?4SE&-Q'%1]4?Z+%++\RO,]Y:Q6'E7R
M'?1F-%CB-_QL[6%5%`*GJJ_RKQR1B.I<6.KF14,<O\[TQ15O^7/F+S%,EW^8
M.K?78%(>/R_8<H;%2-QZIVDGI_E8.(#DS&EG/?*;_H1^AG2Z-I"PQ0+90K!`
MHC@B$:A40?LJM**/EF'GT6',;R0CD/\`3CQ.?`\(H;!M-(TN-U=+2%74@JP1
M001T(VRJ'9FFB1(8\8E'^A%EQGO1>9S%V*NQ5+H?+7EZ#4VU6'3+6/4W+,]Z
MD*+,2XHQ,@'+XOVM\-EK&&`EQ`#B[TQP-CL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5?_UO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
)5V*NQ5V*O__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
